Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against iRhythm, Hut 8, Xponential, and Amplitude and Encourages Investors to Contact the Firm
The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
- The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
- The Zio XT is intended for non-critical patients, as it does not provide real-time reporting.
- These types of heart monitors that are approved for high-risk patients and provide near real-time alerts are also referred to as “real-time” monitors.
- As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.